Trials / Recruiting
RecruitingNCT06290128
A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work
A Phase 3, Double-blind, Placebo-controlled Study Evaluating Efficacy and Safety of Riliprubart in Participants With Refractory Chronic Inflammatory Demyelinating Polyneuropathy
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 140 (estimated)
- Sponsor
- Sanofi · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to evaluate efficacy of riliprubart compared to placebo in adult participants with CIDP whose disease is refractory to standard of care. The study duration will be for a maximum of 111 weeks including screening, treatment phases, and follow-up.
Conditions
- Chronic Inflammatory Demyelinating Polyradiculoneuropathy
- Polyneuropathy, Inflammatory Demyelinating, Chronic
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Riliprubart | Pharmaceutical form: Solution Route of administration: IV Infusion |
| DRUG | Placebo | Pharmaceutical form: Solution Route of administration: IV Infusion |
| DRUG | Riliprubart | Pharmaceutical form: Solution Route of administration: SC Injection |
| DRUG | Placebo | Pharmaceutical form: Solution Route of administration: SC Injection |
Timeline
- Start date
- 2024-07-12
- Primary completion
- 2027-05-17
- Completion
- 2028-11-20
- First posted
- 2024-03-04
- Last updated
- 2026-04-13
Locations
124 sites across 24 countries: United States, Argentina, Belgium, Brazil, Bulgaria, Canada, Chile, China, Czechia, Denmark, France, Germany, Greece, Italy, Japan, Mexico, Netherlands, Poland, Portugal, South Korea, Spain, Sweden, Taiwan, Turkey (Türkiye)
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06290128. Inclusion in this directory is not an endorsement.